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Abstract
Introduction: Diagnostic evaluation of patients with a bleeding tendency remains 
challenging, as no disorder is identified in approximately 50% of patients. An im-
paired interplay of several haemostatic factors might explain bleeding phenotype in 
these patients.
Objective: To investigate whether global haemostasis assays are able to identify hae-
mostatic abnormalities in patients with a bleeding tendency unexplained by current 
diagnostic laboratory tests.
Materials and methods: Patients of ≥12 years with a bleeding tendency were in-
cluded from a tertiary outpatient clinic. Bleeding phenotype was assessed with the 
ISTH-BAT. Patients were classified as having bleeding of unknown cause (BUC) or 
a mild bleeding disorder (MBD) based on abnormalities assessed by routine hae-
mostatic tests. Global haemostasis tests (rotational thromboelastometry (ROTEM), 
thrombin generation test (TG) and plasma clot lysis time (CLT)) were measured in all 
patients. The results were compared with 76 controls.
Results: One hundred and eighty-one patients were included, and 60% (109/181) was 
classified as having BUC. BUC patients demonstrated a significantly prolonged lag 
time in TG (median 7.7 minutes, IQR 6.7-8.7) and a significantly prolonged CLT (me-
dian 60.5 minutes, IQR 54.7-66.1) compared to controls. No differences in ROTEM 
variables were found. Patients with MBD showed an impaired thrombin generation 
with a significantly decreased ETP (median 1024 nmol/L*min, IQR 776-1355) and 
peak height (median 95 nmol/L, IQR 76-138), compared to BUC patients and controls.
Conclusion: No major differences were found in ROTEM and TG variables in BUC 
patients compared to controls. BUC patients did have a significantly prolonged clot 
lysis time. The underlying mechanism for this finding is unknown.
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1  | INTRODUC TION
Patients with a mild bleeding disorder present with varying symp-
toms, such as easy bruising, mucocutaneous bleeding, and bleeding 
after surgery or tooth extraction.1 However, in the general popula-
tion bleeding symptoms are reported in more than 20% of healthy 
individuals2,3 Therefore, diagnostic evaluation of patients with a 
bleeding disorder is a challenging process. Application of routine di-
agnostic laboratory tests in patients with clinically relevant bleeding 
leaves around 50% of patients without a diagnosis. Subsequently, 
these patients are classified as patients with bleeding of unknown 
cause (BUC).4-6 Patients with a clinically relevant bleeding pheno-
type are also regularly diagnosed with mild haemostatic defects 
which may not sufficiently explain the patient's bleeding phenotype 
(mild bleeding disorders, MBD). As a clear diagnosis is lacking in 
these patients, the most appropriate treatment regimen also remains 
uncertain.7
An impaired interplay between several mild haemostatic defects 
may explain bleeding phenotype in this patient category. Global hae-
mostatic assays may increase insight into the pathogenesis of BUC, 
as other components of the haemostatic system on blood coagu-
lation are investigated more thoroughly.8 Rotational thromboelas-
tometry (ROTEM) provides a graphical representation of blood clot 
formation and fibrinolysis, which includes contributions of erythro-
cytes, leucocytes and platelets.9 Measurement of thrombin genera-
tion (TG) has also been proposed as a promising approach to globally 
estimate an individual's coagulation potential and to predict a hypo- 
or hyper-coagulable state.10 In addition, investigation of fibrinolysis 
is often omitted in the routine work-up of patients with a bleeding 
tendency. It is however known that clots made from the plasma of 
haemophilia patient show altered characteristics and higher suscep-
tibility to fibrinolysis.11,12
In order to gain more insight into the pathophysiological mecha-
nisms of bleeding symptoms in patients with BUC and MBD, and to 
investigate the diagnostic value of global haemostasis tests in these 
patients, we investigated the role of these global tests in the diag-
nostic work-up.
2  | MATERIAL S AND METHODS
2.1 | Study population
Patients, aged 12 years or older, referred to the outpatient haema-
tology and paediatric haematology clinics of our tertiary clinics, the 
Erasmus University Medical Center and Sophia Children's Hospital, 
for haemostatic screening between 1 June 2016 and 1 March 2018 
due to a clinically relevant bleeding tendency were prospectively in-
cluded. Patients previously diagnosed with a bleeding disorder or 
diagnosed with an established bleeding disorder after a first labo-
ratory panel (eg von Willebrand's disease, haemophilia or platelet 
disorder), patients using anticoagulant, antiplatelet or nonsteroidal 
anti-inflammatory drugs, pregnant women and women <3 months 
postpartum were not eligible for study inclusion. A total of 76 sex-
matched healthy individuals were included as control group. These 
healthy individuals were recruited among employees and students 
of the Erasmus MC University Medical Center. This study was sub-
ject to the Medical Research Involving Human Subjects Act and ap-
proved by the Medical Ethics Committee of the Erasmus University 
Medical Center Rotterdam (MEC-2016-218). Written informed con-
sent was obtained from each participant.
2.2 | Medical bleeding history and bleeding 
assessment tool
Upon inclusion, all surgical interventions, tooth extractions, obstet-
ric history and detailed family history were documented. A bleeding 
score (BS), based on the history of bleeding events, was calculated 
by the ISTH-Bleeding Assessment Tool (ISTH-BAT), with cut-off val-
ues ≥4 in males, ≥6 in females and ≥3 in children.13,14
2.3 | Blood sampling and laboratory assays
Laboratory tests were performed in a stepwise manner. The first 
step included a full blood count, ABO blood type, prothrombin time 
(PT), activated partial thromboplastin time (aPTT), fibrinogen con-
centration according to von Clauss, determination of VWF antigen 
(VWF:Ag), activity (VWF:GPIbM) and collagen binding (VWF:CB), 
one-stage assay FVIII:C and FIX:C and VWF-multimer analysis in 
case of low VWF. Platelet function was assessed with the collagen-
epinephrine and collagen-ADP cartridges on the platelet func-
tion analyzer (PFA-200). As second step, FVII:C, FXI:C and FXIII:C, 
α2-antiplasmin, and light transmission aggregometry (LTA) were 
performed. Measurements of VWF:Ag/Act/CB and FVIII:C were re-
peated at least once.
Blood sampling was performed using the Vacutainer system 
(Becton Dickinson) containing sodium citrate (final concentration 
0.109 mol/L) or EDTA (1.8 mg/mL, Plymouth). Citrated blood was cen-
trifuged at 2000 g for 10 minutes at room temperature, followed by 
14 000 g for 10 minutes centrifugation of plasma at room temperature. 
Platelet poor plasma (PPP) samples were stored in aliquots at −80°C 
until analysis, when indicated. Routine coagulation tests aPTT (Actin 
FS), PT (Thromborel S) and fibrinogen (Thrombin Reagent) were mea-
sured on a Sysmex CS-5100 (Siemens Healthcare Diagnostics BV). 
Collagen-ADP (C-ADP) and collagen-epinephrine (C-Epi) cartridges 
were used to measure closure times (CT, seconds) on the PFA-200 
(Siemens). Light transmission aggregometry (LTA) was performed on 
a Chrono-Log aggregometer 490 (Stago Benelux BV). VWF:Ag levels 
and VWF:CB activity were determined with an in-house ELISA assay. 
VWF activity (VWF:GPIbM) was determined with the INNOVANCE 
VWF Ac assay (Siemens) on a Sysmex CS-5100. FVIII:C and FIX:C were 
measured using one-stage clotting assays and derived from the prolon-
gation of the clotting time (aPTT) measured on the Sysmex CS-5100 
(Siemens). FXIII activity was measured using the Berichrom® FXIII kit 
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(Siemens) on the Sysmex CS-5100 (Siemens). Alpha 2-antiplasmin level 
was measured using a chromogenic assay (Stachrom, Stago) on the 
Sysmex CS-5100 (Siemens).
2.4 | Rotational thromboelastometry
Viscoelastic clotting measurements were performed with ROTEM® 
Delta (Tem International xGmbH) tests according to the manufac-
turer's protocol. All investigations were performed within 2 hours 
after blood collection and the assays ran for 60 minutes. Extrinsic 
and intrinsic coagulation was measured with the EXTEM and the 
INTEM assays. The influence of fibrinogen on clot firmness was 
estimated with the platelet-inactivated FIBTEM assay. The follow-
ing ROTEM parameters were analysed: clotting time (CT, sec); clot 
formation time (CFT, sec); maximum clot firmness (MCF, mm); and 
maximal lysis (ML, %).
2.5 | Thrombin generation
Thrombin generation was assessed using the calibrated auto-
mated thrombogram (CAT) assay (Diagnostica Stago) in accordance 
with the manufacturers’ instructions, as described previously.15,16 
Briefly, PPP was added to PPP Reagent 1 pm TF (PPP-Reagent LOW, 
Thrombinoscope BV), which consists of a mixture of tissue factor 
(TF; 1 pm final concentration in plasma) and phospholipids. Plasma 
of each subject was analysed in duplicate. Acquisition of thrombin 
generation parameters was performed using the Thrombinoscope 
software (Diagnostica Stago; CAT). Four parameters were derived 
from the thrombin generation curve: lag time (min), time to peak (tt-
peak, min), endogenous thrombin potential (ETP, nmol/L*min) and 
peak height (nmol/L).
2.6 | Plasma clot lysis assay
The plasma clot lysis assay was performed as described before.17,18 
PPP was diluted in buffer (25 mmol/L Hepes, 137 mmol/L NaCl, 
3.5 mmol/L KCl, 1% (w/v) BSA, pH 7.4). The diluted plasma was 
added to a reaction mixture, containing tissue factor (TF, Innovin, 
1000 times diluted; Dade Behring), CaCl2 (17 mmol/L), tPA 
(30 ng/mL, Actilyse, Boehringer Ingelheim), phospholipid vesicles 
(10 µmol/L, Rossix Mölndal) and potato carboxypeptidase inhibi-
tor (PCI, an inhibitor of activated TAFI) (30 µg/mL) when indicated. 
The concentrations refer to the final concentrations in the clot. 
In a microplate reader (VictorTM, PerkinElmer), the optical density 
at 405 nm was measured every minute for 300 minutes at 37°C. 
The clot lysis time (CLT) was the time from midpoint of minimum 
turbidity to maximum turbidity, which represents clot formation, 
to the midpoint of maximum turbidity to minimum turbidity, which 
represents clot lysis. CLTs with and without the addition of PCI 
were measured in duplicate.
2.7 | Reference ranges
Reference ranges for ROTEM, thrombin generation and plasma 
clot lysis time are based on 76 healthy controls, calculated with the 
Reference Value Advisor software (v2.1) which closely follows the 
CLSI guideline.19,20
2.8 | Definition of diagnoses
A MBD was defined as the presence of a hereditary bleeding dis-
order, specified as follows: low VWF—VWF activity levels between 
0.30-0.50 U/mL and ratio of FVIII:C to VWF:Ag > 0.6 21; PFD: ab-
normalities found using light transmission aggregation testing (LTA), 
not fitting the pattern of any known platelet function disorder 22; 
and isolated coagulation factor deficiency: deficiency of a coagula-
tion factor, other than FVIII (haemophilia A) or FIX (haemophilia 
B), with laboratory criteria as proposed by the European Network 
of Rare Bleeding Disorders.6,23 Bleeding was considered as bleed-
ing of unknown cause (BUC) based on the absence of haemostatic 
abnormalities after extensive laboratory investigation, as described 
before.1,7,24
2.9 | Statistics
We used descriptive statistics to summarize baseline character-
istic of the study population. In case of a skewed distribution, 
data are presented as median and interquartile range (IQR), and 
compared by a Mann-Whitney U test. In case of a normal distri-
bution, data are presented as mean and standard deviation (SD) 
and compared using an independent sample t test. Categorical 
data are presented as numbers with percentages and compared 
using a Pearson Chi-square test. In multiple logistic regression, 
models were adjusted for age, sex, BMI, platelet count, fibrinogen, 
VWF, FVIII:C and FXIII:C as appropriate. Outcomes are reported 
as odds ratios (ORs) followed by the 95% confidence interval (CI). 
Multiplicity correction was not performed because of the hypoth-
esis-generating approach of the study. A P-value of <.05 was con-
sidered statistically significant. All analyses were performed with 
SPSS version 24.0 (IBM, Armonk, NY, USA).
3  | RESULTS
One hundred and eighty-one patients were referred to our hospital 
with a clinically relevant bleeding tendency and eligible for inclusion, 
and 76 healthy individuals were included as healthy controls. The 
majority of study participants was female (84% of patients and 86% 
of healthy controls). Mean age was 33.6 years (SD 17.3) for patients, 
with 53/181 (29%) adolescent patients ≥ 12 years, and 35.8 years 
(SD 12.3) for healthy controls, see Table 1. For study protocol and 
flow of inclusion see Figure 1.
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A total of 120/181 (66%) patients were classified as having 
BUC. Sixty patients were classified as having a MBD, with platelet 
function disorders (43%) and low VWF (35%) being most preva-
lent. BUC patients consisted of a higher percentage of adults (80% 
versus 52% in MBD, P < .01) and had a higher median age (33 year, 
IQR 24-50 year) than MBD patients (20 year, IQR 15-39 year, 
P < .01). Significantly less BUC patients had blood type O (40%) 
than MBD patients (53%, P < .05). BUC patients had a median BS 
of 5 (IQR 3-8), compared to a median BS of 7 (IQR 6-9) in patients 
with MBD (P < .01), with only 54% of BUC patients presenting 
with an abnormal BS, compared to 88% of MBD patients (P < .01) 
(see Table 1).
As expected, patients with MBD had significantly lower lev-
els of VWF:Ag, VWF:GPIbM, VWF:CB and FVIII:C than BUC pa-
tients. Also, MDB patients had a significantly lower platelet count 
and increased aPTT. No differences in haemostatic variables were 
found between BUC patients and healthy controls (see Table 2 and 
Figure 2). When excluding patients with a normal bleeding score, sig-
nificantly lower levels of VWF:Ag, VWF:GPIbM, VWF:CB, FVIII:C 
and FIX:C-level were found in MBD patients compared to BUC pa-
tients (see Table 2).
When comparing BUC patients and healthy controls, no statis-
tically significant differences were observed in thromboelastome-
try variables (see Figure 2 and Table S1). When adjusting for age, 
sex, BMI, platelet count, fibrinogen, VWF:GPIbM and FVIII:C levels 
by means of logistic regression analysis, no significant differences 
were found between BUC patients and healthy controls (Table S2). 
Comparing BUC patients with MBD patients, BUC patients had a 
significantly decreased clot formation time (CFT) in the EXTEM and 
INTEM assay, and a significantly increased maximum clot firmness 
(MCF) in the EXTEM, INTEM and FIBTEM assay (see Figure 2 and 
Table S1).
BUC patients had a significantly longer lag time (median 7.7 min-
utes, IQR: 6.6-8.7 minutes) compared to healthy controls (median 
6.9 minutes, IQR: 6.0-8.6 minutes, P < .05). Other thrombin genera-
tion parameters were not different between BUC patients and healthy 
controls (Table S1). When adjusting for age, sex, BMI, platelet count, 
fibrinogen and FXIII:C levels by means of logistic regression analysis, 
also no significant differences were found between BUC patients and 
healthy controls (Table S2). In MBD patients, impaired thrombin gen-
eration was found, with a significantly decreased ETP and peak height 
compared to BUC patients (see Figure 2) and healthy controls.
TA B L E  1   Study group characteristics
 
Bleeding of Unknown Cause (BUC) 
(n = 121)
Healthy controls 
(HC) (n = 76) Pc 
Mild bleeding disorder (MBD) 
(n = 60) Pd 
Age, median [IQR] 33 [24-50] 32 [26-46] n.s. 20 [15-39] .001
Adults, n (%) 97 (80%) 76 (100%) .000 31 (52%) .000
Female, n (%) 105 (87%) 65 (86%) n.s. 47 (78%) n.s.
BMI, median [IQR] 26.5 [22.4-29.8] 23.6 [21.8-27.3] .020 24.0 [20.3-27.5] .047
Bleeding score, median 
[IQR]
5 [3-8] 0 [0-2] .000 7 [6-9] .001
Abnormal bleeding scorea , 
n (%)
65 (54%) 1 (1%) .000 51 (88%) .000
Blood group O, n (%) 48 (40%) 28 (38%) .036 31 (53%) .049
Positive family historyb , 
n (%)
37 (31%) 0 (0%) n.a. 28 (48%) n.s.
Presenting symptom, (%) Haematomas 31% n.a. - Haematomas 32% -
Postsurgical bleeding 18% Postsurgical bleeding 22%
Postpartum haemorrhage 15% Family history 20%
Referring physician, (%) Haematologist from local 
hospital
29% n.a. -  Paediatrician 35% -
General practitioner 22% General practitioner 24%
Gynaecologist 19% Haematologist from local 
hospital
22%
Note: Data are shown as median and interquartile range [25th-75th percentile], and number and percentage, as appropriate.
Abbreviations: BMI, body mass index; BUC, bleeding of unknown cause; HC, healthy controls; MBD, mild bleeding disorder; n.a., not applicable; n.s., 
nonsignificant.
aAbnormal bleeding scores: ≥6 for females, ≥4 for males, ≥3 for adolescents. 
b1st, 2nd or 3rd degree family member diagnosed with a bleeding disorder or evaluated at a haematology outpatient department for a bleeding 
tendency. 
cComparison of BUC patients and healthy controls. 
dComparison of BUC patients and patients with a MBD. 
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Remarkably, a significant longer CLT in BUC patients (PCI- me-
dian 60.3 minutes, IQR 54.7-66.0 minutes and PCI + 41.3 minutes, 
IQR 38.0-46.2 minutes) was found compared to healthy controls 
(PCI- median 57.4 minutes, IQR 53.9-61.7 minutes and PCI + 38.9, 
IQR 36.3-42.5 minutes, P = .03 and P < .01 respectively) (Table S1). 
However, when adjusting for age, sex, BMI, platelet count, fibrino-
gen and FXIII:C levels by means of logistic regression analysis, no sig-
nificant differences were found between BUC patients and healthy 
controls (Table S2). Overall, no differences were found in CLT be-
tween BUC patients and MBD patients, both with and without ad-
justment for age, sex, BMI, platelet count, fibrinogen and FXIII:C 
levels.
In thromboelastometry, thrombin generation and clot lysis time 
variables, no additional significant differences were found between 
BUC and MBD patients, after excluding patients with a normal 
bleeding score (see Table 2 and Table S1).
The ETP was significantly lower in patients with an abnormal 
bleeding score (median 1223 nmol/L*min, IQR: 923-1516 nmo-
l/L*min) compared to patients with a normal bleeding score (me-
dian 1055 nmol/L*min, IQR: 828-1363 nmol/L*min, P = .046). 
Furthermore, patients with an abnormal bleeding score had a sig-
nificantly longer CT (median 65 minutes, IQR: 58-72 minutes) in the 
EXTEM assay and significantly lower MCF (median 16 mm, IQR: 
13-19 mm) in the FIBTEM assay compared to patients with a normal 
score (CT-EXTEM: median 67 minutes, IQR: 63-73 minutes, P = .048 
and MCF-FIBTEM: median 15 mm, IQR: 11-18 mm, P = .04). Plasma 
clot lysis time was comparable in patients with an abnormal and nor-
mal bleeding score (see Figure 3 and Table S4).
4  | DISCUSSION
This study reports on a cohort of 181 patients referred for analy-
sis of a bleeding tendency in whom no major bleeding disorder was 
diagnosed. After routine haemostatic testing, 66% of patients re-
mained undiagnosed and were classified as having bleeding of un-
known cause (BUC). The other 34% of patients were diagnosed with 
a mild bleeding disorder (MBD).
We found that rotational thromboelastometry variables are within 
reference ranges in BUC patients and do not differ from healthy con-
trols and MBD patients. Our results are in line with those recently 
described by Wieland Greguare-Sander et al25 and support their con-
clusion that there is no support for the additive value of rotational 
thromboelastometry for screening and diagnosing patients with a 
F I G U R E  1   Flow chart of study protocol and inclusion. aPTT, activated partial thromboplastin time; BUC, bleeding of unknown cause; 
FIX, factor IX; FVII, factor VII; FVIII, factor VIII; FXI, factor XI; FXIII, factor XIII; LTA, light transmission aggregometry; MBD, mild bleeding 
disorder; No BD, no bleeding disorder; PFA-Col/Epi, platelet function analyser collagen/epinephrine; PFD, platelet function disorder; PT, 
prothrombin time; VWF, von Willebrand factor
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(mild) bleeding tendency. Thrombin generation has been applied 
regularly to investigate bleeding risk in patients with a bleeding dis-
order.26,27 In this study, besides a significant longer lag time in BUC 
patients, thrombin generation parameters did not differ between pa-
tients with BUC and healthy controls, as also shown in previous stud-
ies.28,29 This finding was, however, in contrast with recently published 
data,24 in which all the TG variables in BUC patients were found to be 
significantly different from healthy controls. Patients with MBDs did 
show a significantly impaired thrombin generation, with a decreased 
endogenous thrombin potential (ETP) and peak height. This finding is 
remarkable, however, as the used thrombin generation is a reflection 
of secondary haemostasis, and most patients in the MBD group are 
diagnosed with a disorder of primary haemostasis. Also, no evidence 
was found supporting a systemic hyperfibrinolytic capacity in BUC 
patients. In contrast, we found that clot lysis time was significantly 
prolonged in BUC patients compared to healthy controls, in line with 
TA B L E  2   Haemostatic variables in different patient groups and healthy controls
 Na  BUC Na  HC Pc  Na  MBD Pd 
Haemoglobin, mmol/L 115 8.1 [7.8-8.8] 75 8.2 [7.8-8.7] n.s. 55 8.6 [8.1-9.0] .015
61b  8.1 [7.9-8.8] n.a.  n.s. 47b  8.7 [8.2-9.1] .006
Platelet count, 109/L 113 272 [236-317] 75 253 [224-300] n.s. 58 248 [208-283] .010
59b  276 [229-328] n.a.  n.s. 49b  238 [207-278] .012
PT, sec 116 11.9 [11.4-12.5] 76 11.9 [11.5-12.6] n.s. 56 11.7 [11.4-12.7] n.s.
61b  11.7 [11.2-12.5] n.a.  n.s. 48b  11.7 [11.4-12.6] n.s.
APTT, sec 121 25 [23-26] 76 25 [23-26] n.s. 60 26 [24-27] .010
63b  25 [24-26] n.a.  n.s. 51b  26 [24-27] .026
PFA, sec 117 137 [118-160] 76 136 [109-157] n.s. 52 151 [126-176] n.s.
63b  137 [118-159] n.a.  n.s. 44b  151 [123-173] n.s.
Fibrinogen, g/L 120 2.8 [2.4-3.4] 76 2.7 [2.3-3.4] n.s. 58 2.7 [2.4-3.2] n.s.
64b  2.8 [2.4-3.3] n.a.  n.s. 49b  2.7 [2.4-3.3] n.s.
VWF:Ag, U/mL 120 0.98 [7.3-1.22] n.a. n.a. n.a. 59 0.73 [0.55-1.04] .000
64b  0.91 [0.73-1.18] n.a.  n.a. 50b  0.79 [0.79-1.02] .003
VWF:Act, U/mL 121 0.89 [0.75-1.22] 76 0.93 [0.77-1.24] n.s. 59 0.74 [0.54-1.02] .001
65b  0.89 [0.76-1.12] n.a.  n.s. 50b  0.79 [0.54-1.04] .026
VWF:CB, U/mL 120 0.87 [0.70-1.09] n.a. n.a. n.a. 59 0.69 [0.48-0.96] .000
64b  0.84 [0.70-1.07] n.a.  n.a. 50b  0.70 [0.52-0.97] .002
FVIII:C, U/mL 121 1.20 [1.05-1.40] 75 1.23 [1.13-1.53] n.s. 59 1.06 [0.79-1.21] .000
65b  1.18 [1.07-1.34] n.a.  n.s. 50b  1.08 [0.84-1.22] .001
FVII:C, U/mL 46 0.88 [0.78-1.10] 40 0.98 [0.80-1.16] n.s. 26 0.91 [0.74-1.13] n.s.
26b  0.86 [0.69-1.16] n.a.  n.s. 22b  0.91 [0.73-1.13] n.s.
FIX:C, U/mL 109 1.05 [0.96-1.15] 40 1.02 [0.94-1.17] n.s. 58 1.01 [0.92-1.13] n.s.
62b  1.08 [0.97-1.18] n.a.  n.s. 49b  1.00 [0.90-1.15] .040
FXI:C, U/mL 107 1.05 [0.96-1.15] 40 1.07 [0.98-1.16] n.s. 57 1.00 [0.93-1.12] n.s.
59b  1.06 [0.99-1.17] n.a.  n.s. 48b  1.00 [0.93-1.12] n.s.
FXIII:C, U/mL 112 1.28 [1.11-1.41] 40 1.30 [1.08-1.38] n.s. 59 1.23 [1.06-1.31] n.s.
62b  1.23 [1.04-1.42] n.a.  n.s. 50b  1.23 [1.06-1.33] n.s.
Alpha-2-antiplasmin, U/mL 88 1.15 [1.05-1.21] n.a. n.a. n.a. 42 1.15 [1.04-1.19] n.s.
53b  1.15 [1.09-1.22] n.a.  n.a. 37b  1.14 [1.03-1.19] n.s.
Note: Data are shown as median and interquartile range [25th-75th percentile].
Abbreviations: aPTT: activated partial thromboplastin time; BUC: bleeding of unknown cause; FIX:C: factor IX activity; FVII:C factor VII activity; 
FVIII:C: factor VIII activity; FXI:C: factor XI activity; FXIII:C: factor XIII activity; HC: healthy controls; MBD: mild bleeding disorder; n.a.: not 
applicable; n.s.: nonsignificant; PFA: platelet function analyzer; PT: prothrombin time; VWF:Act: von Willebrand factor activity; VWF:Ag: von 
Willebrand factor antigen; VWF:CB: von Willebrand factor collagen binding.
aBased on available data. 
bNo of patients with abnormal bleeding score. 
cComparison of BUC patients and healthy controls. 
dComparison of BUC patients and patients with a MBD. 
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previously published data,30,31 hereby carefully rejecting hyperfibri-
nolysis as underlying pathophysiological mechanism for BUC.
Several studies have shown that between 47% and 69% of pa-
tients will remain undiagnosed after extensive and repeated labo-
ratory testing.1,4 When no laboratory abnormalities are found, the 
medical history and a bleeding score are important tools for physi-
cians.6,32 However, the ISTH-BAT has shown to only have a limited 
role, as a normal score was present in 44% of BUC patients and in 
21% of MBD patients. Therefore, a BAT should only serve as one 
of the many diagnostic tools available in the diagnostic work-up of 
these patients.
We confirm one of the main findings by Gebhart et al, namely, 
that the majority of patients being referred for bleeding symptoms 
is female (>80%) and that more women than men are categorized 
with BUC, hereby possible affirming that there is a sex-related 
difference in BUC rate.1 Women have a higher chance of mani-
fest bleeding due to menstrual cycle and women's ability for child 
birth. Other mechanisms however, such as the influence of female 
hormones on skin and muscle possibly leading to easy bruising, are 
still largely unknown.33 We also showed that patients with BUC 
were significantly older than patients with a diagnosed MBD. It 
has been shown that several haemostatic factors increase with 
age.34 This may explain that no abnormalities were found in this 
‘older’ subgroup at time of analysis. Also, the role of comorbidities 
can be more pronounced in an older population, for example the 
influence of age and comorbidities on skin and vessels, possibly 
causing easy bruising or perioperative bleeding.35 To our knowl-
edge, this is also one of the first studies to report BUC in adoles-
cents, with a higher percentage of adolescents being diagnosed 
with a MBD than adults.
Our study has some limitations. First, one cannot exclude a possi-
ble referral bias for adolescents, with investigations possible being de-
layed or abandoned if the bleeding score was not very high. This might 
explain the increased rate of adolescents as well as the higher bleeding 
scores in the MBD patient group. We performed LTA for investigation 
of platelet function disorders. An influence of comedications on plate-
let function cannot be ruled out completely. For example, we did not 
exclude patients using selective serotonin reuptake inhibitors (SSRIs), 
which are shown to reduce platelet function.36,37 Due to the circadian 
rhythm of plasminogen activator inhibitor-1 (PAI-1), which inhibits 
F I G U R E  2   Haemostatic, thromboelastometry, thrombin generation and plasma clot lysis assay variables in patients and healthy controls. 
EXTEM ML × 10; INTEM CT/10; INTEM ML × 10; FIBTEM ML × 10; Lag time × 10; ETP/10; Time to peak × 10. BUC, bleeding of unknown 
cause; CFT, clot formation time; CLT, clot lysis time; CT, clotting time; ETP, endogenous thrombin potential; FIX:C, factor IX activity; FVII:C, 
factor VII activity; FVIII:C, factor VIII activity; FXI:C, factor XI activity; FXIII:C, factor XIII activity; MBD, mild bleeding disorder; MCF, 
maximum clot firmness; ML, maximum lysis; PCI, potato carboxypeptidase inhibitor; VWF, von Willebrand factor. †P < .05, BUC patients 
compared to healthy controls. ‡P < .05, BUC patients compared to MBD patients
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fibrinolysis and increases in the morning,38 we attempted to collect 
blood for plasma clot lysis assay in the afternoon. Unfortunately, this 
was not always possible due to logistic reasons.
Additional studies on patients without a clear diagnosis are re-
quired. In the near future, advanced techniques such as next-gen-
eration sequencing (NGS)–based gene panels39 or whole-exome 
sequencing (WES)40 may lead to discoveries of novel haemostatic 
modifiers. However, translating these results will provide a next 
challenge due to multi-interpretable and uncomprehensive findings 
such as variants of unknown significance (VUS).
5  | CONCLUSION
No major differences were found in thromboelastometry variables 
and thrombin generation in patients with bleeding of unknown 
cause (BUC), compared to healthy controls. BUC patients did have 
a significantly prolonged clot lysis time, possibly indicating an 
impaired or decreased fibrinolysis. In MBD patients, an impaired 
thrombin generation was found. At this point, however, we do not 
recommend implementation of thromboelastometry, measure-
ment of thrombin generation and measurement of plasma clot 
lysis time in the diagnostic process of patients with bleeding of 
unknown cause.
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